Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Jul 3:12:2023-4-3.
doi: 10.7573/dic.2023-4-3. eCollection 2023.

Real-world management of abnormal scarring using topical silicone gel: expert consensus and case series from the Asian SCARS Expert Group

Xiaonan Yang  1 , Visnu Lohsiriwat  2 , Frank Chun Shin Chang  3 , Tan Thiam Chye  4 , Catherine J Howard  5   6 , Liang Qiao  7 , Steven W Shaw  8 , Tu Nguyen Anh Tran  9 , Chan Yung  10 , Daniel Dellosa  11 , Dinesh Nagrale  11
Affiliations
Case Reports

Real-world management of abnormal scarring using topical silicone gel: expert consensus and case series from the Asian SCARS Expert Group

Xiaonan Yang et al. Drugs Context. .

Erratum in

Abstract

Preventing abnormal scar formation and correcting non-aesthetic mature scars are important to prevent physical and psychosocial consequences of abnormal scarring. Evidence-based guidelines for scar management in Asian patients recommend first-line silicone-based products. Dermatix®* Ultra and Dermatix Ultra Kids are topical silicone gels containing a vitamin C ester that helps lighten scar tissue. Herein, we report a case series including patients with hypertrophic and keloid scars treated with Dermatix, showing that Dermatix is effective for scar treatment and prevention, as well as expert consensus supporting the safe and effective use of Dermatix.

Keywords: adults; hypertrophic scars; keloid; paediatric; real-world; scar prevention; scar treatment; topical silicone gel.

PubMed Disclaimer

Conflict of interest statement

Disclosure and potential conflicts of interest: XY, VL, FC, LQ, SS, TT, and YC declare no conflicts of interest. TC declares receiving an honorarium for the expert meeting. CH declares payment or honoraria for lectures, presentations, speakers, bureaus, article writing, or educational events from Biofemme Unilab, Philippine Family Physician, Bayer, Cardinal Santos Medical Center and Quezon City Medical Society, support for attending meetings and/or travel from Cathay Drug Philippines and Biofemme Unilab, and a leadership or fiduciary role at Cardinal Santos Medical Center. DD and DN are employees of A. Menarini Asia-Pacific Pte. Ltd. The International Committee of Medical Journal Editors Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2023/06/dic.2023-4-3-COI.pdf

Figures

Figure 1
Figure 1
Improvement in scarring in a 26-year-old man with third-degree burns to his face, neck and anterior upper trunk following 90 days Dermatix Ultra application (case 1). (A) Pre-treatment; (B) Post-treatment (3 months).
Figure 2
Figure 2
Improvement in scarring in a 5-year-old boy with second-degree facial scald injury treated with wound debridement, 2-week xenograft, and Dermatix Ultra silicone gel for 7 weeks (case 2). (A) day 1; (B) day 14; (C) day 60.
Figure 3
Figure 3
7-year-old boy with an erythematous and hypertrophic scar treated with laser treatment (pulsed dye laser) every 4 weeks plus topical Dermatix Ultra silicone gel (case 3). (A) Pre-treatment; (B) After 1 round of treatment; (C) After 2 rounds of treatment; (D) After 3 rounds of treatment.
Figure 4
Figure 4
Improvement in facial scarring in a 45-year-old man following 2 sessions of laser therapy and 3 months of Dermatix Ultra silicone gel treatment (case 4). (A) and (C) Pre-treatment; (B) and (D) Post-treatment (3 months).
Figure 5
Figure 5
Improvement in scarring in a 25-year-old woman undergoing lower eyelid surgery treated with Dermatix Ultra silicone gel (case 5). (A) Pre-surgery; (B) 2 months post-surgery; (C) 3 months post-surgery; (D) 6 months post-surgery; (E) 11 months post-surgery.
Figure 6
Figure 6
Improvement of scarring in a 35-year-old woman post-revisional breast surgery treated with Dermatix Ultra silicone gel (case 6). (A) 2-year post-revisional breast surgery scar treated with Dermatix Ultra silicone gel; (B) Dermatix Ultra-treated 2-year post-revisional breast surgery scar compared with untreated 6-month post-surgical abdominal scar; (C) Untreated 3-month post-surgical abdominal scar showing hypertrophic scar formation (untreated site).
Figure 7
Figure 7
Newborn child with scarring following surgery for bilateral complete cleft lip and palate treated with botulinum toxin injection and 6-month Dermatix Ultra Kids silicone gel (case 7). (A) Post-surgical scarring; (B) 9-month follow-up.
Figure 8
Figure 8
Improvement in scarring in a 45-year-old man with hypopigmented, atrophic, and hypertrophic scar on his nose treated with four rounds of fractional ablative CO2 laser surgery plus topical Dermatix Ultra silicone gel (case 8). (A) Pre-treatment; (B) Post-treatment (4 months).
Figure 9
Figure 9
Improvement in caesarean section scar in a 30-year-old woman following application of Dermatix Ultra silicone gel from 2 weeks post-surgery for 6 months (case 9). (A) Pre-treatment; (B) 10 days post-surgery; (C) 1-month post-surgery; (D) 6 months post-surgery.
Figure 10
Figure 10
No keloid scar formation after 6 months of treatment with Dermatix Ultra silicone gel; the patient (currently aged 42 years) has a nice, flat 1-line scar (pre-treatment photo not available) (case 11).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Wolfram D, Tzankov A, Pülzl P, Piza-Katzer H. Hypertrophic scars and keloids—a review of their pathophysiology, risk factors, and therapeutic management. Dermatol Surg. 2009;35(2):171–181. doi: 10.1111/j.1524-4725.2008.34406.x. - DOI - PubMed
    1. Gauglitz GG. Management of keloids and hypertrophic scars: current and emerging options. Clin Cosmet Investig Dermatol. 2013;6:103–114. doi: 10.2147/CCID.S35252. - DOI - PMC - PubMed
    1. Monstrey S, Middelkoop E, Vranckx JJ, et al. Updated scar management practical guidelines: non-invasive and invasive measures. J Plast Reconstr Aesthet Surg. 2014;67(8):1017–1025. doi: 10.1016/j.bjps.2014.04.011. - DOI - PubMed
    1. Poetschke J, Gauglitz GG. Current options for the treatment of pathological scarring. J Dtsch Dermatol Ges. 2016;14(5):467–477. doi: 10.1111/ddg.13027. - DOI - PubMed
    1. Ahn ST, Monafo WW, Mustoe TA. Topical silicone gel: a new treatment for hypertrophic scars. Surgery. 1989;106:781–787. - PubMed

Publication types